BSF Enterprise shares soar as it agrees 10-year global cosmetics deal
BSF Enterprise PLC on Tuesday said it has agreed a worldwide exclusive commercialisation and supply partnership for its ETSYL bioactive peptide with SCHAKAU Managementberatung GmbH.
The London-based biotechnology company said SCHAKAU, a German consultancy specialising in commercialising luxury beauty brands, will receive exclusive global commercialisation, distribution and licensing rights for ETSYL, a peptide developed by BSF subsidiary 3D Bio-tissues Ltd, for use in cosmetics and skincare.
BSF said the partnership has established a "capital-light, highly scalable model", with SCHAKAU responsible for taking ETSYL into the cosmetics and skincare markets.
Following the announcement, shares in BSF rose 18% to 1.19 pence on Tuesday afternoon in London.
SCHAKAU will receive exclusive rights for an initial 10-year period, subject to annual volume targets.
SCHAKAU has allocated an estimated EUR300,000 to fund clinical claim substantiation, regulatory compliance, brand development and international distribution. It will be responsible for downstream regulatory costs and clinical efficacy testing.
BSF will supply ETSYL through 3D bio-tissues, generating manufacturing revenue under a volume-based pricing structure. Initial supply revenue is expected during a 12-month product preparation phase ahead of retail launch.
ETSYL, also known as palmitoyl pentapeptide-87, was originally developed for tissue engineering applications but has potential uses in skincare through its ability to stimulate collagen production.
Net licensing income from third-party brand integrations will be split equally between BSF and SCHAKAU after external compliance and patent costs.
BSF will retain full ownership of the intellectual property, patents, trade secrets and manufacturing know-how relating to ETSYL.
SCHAKAU plans to use ETSYL as the core active ingredient in its HANDS OF GOD luxury skincare brand and to pursue licensing agreements with other cosmetics brands.
Chief Executive Che Connon said: "By partnering with Nico and the team at SCHAKAU, we have established a capital-light, highly scalable model. SCHAKAU is funding downstream clinical, regulatory, and brand launch costs, allowing BSF to capture manufacturing supply revenues and 50% of global licensing income, while retaining 100% ownership of our core patent stack."
BSF did not disclose a value for the supply agreement or expected licensing revenue.
Copyright 2026 Alliance News Ltd. All Rights Reserved.